RxDoctor Payments Data

Ryan Cahill, DO

Family Medicine · Deer Park, NYNPI 1437250032

Payments from drug & device makers

$517in general payments, 2019–2025

Across 20 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$112
  • Lilly USA, LLC$93
  • Novo Nordisk$79
  • Otsuka America Pharmaceutical, Inc.$45
  • Exact Sciences$42
  • Boehringer Ingelheim$36
  • plus $110 from 4 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$378,468
Medicare patients
372
Services billed
5,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$98,158
JardianceEmpagliflozin118$83,408
RybelsusSemaglutide27$61,666
OzempicSemaglutide28$46,978
FarxigaDapagliflozin Propanediol50$37,921
LokelmaSodium Zirconium Cyclosilicate37$23,522
XareltoRivaroxaban58$20,846
Janumet XrSitagliptin Phos/Metformin Hcl13$20,027
ProcritEpoetin Alfa18$19,240
EntrestoSacubitril/Valsartan52$17,730
JanuviaSitagliptin Phosphate34$15,567
Jentadueto XrLinagliptin/Metformin Hcl12$12,017
BrilintaTicagrelor44$11,034
Budesonide48$9,071
RestasisCyclosporine19$6,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$79$108,64455 claims
Boehringer IngelheimJardiance, Jentadueto Xr, Pradaxa$36$97,998161 claims
AstraZenecaFarxiga, Lokelma, Brilinta$34$72,478131 claims
AbbVieRestasis, Synthroid, Alphagan P$26$11,55879 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Deer Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →